Journal article
Increased Program Cell Death-1 Expression on T Lymphocytes of Patients With Progressive Multifocal Leukoencephalopathy
Journal of acquired immune deficiency syndromes (1999), Vol.60(3), pp.244-248
07/01/2012
DOI: 10.1097/QAI.0b013e31825a313c
PMCID: PMC3400136
PMID: 22549384
Abstract
The cellullar immune response is important in the containment of progressive multifocal leukoencephalopathy (PML). We examined program cell death-1 (PD-1) expression, a marker of cellular immune exhaustion, on T lymphocytes in PML. PD-1 expression was elevated on total CD4(+) and CD8(+) T cells (medians 36% and 24%) in PML patients compared with healthy control subjects (medians 14% and 18%; P = 0.0015 and P = 0.033). In PML patients, JC virus (JCV)-specific CD8(+) cytotoxic T lymphocytes expressed PD-1 more frequently than total CD8(+) T lymphocytes (means 39% and 78%, P = 0.0004). Blocking the PD-1 receptor increased JCV-specific T-cell immune response in a subgroup of PML patients.
Details
- Title: Subtitle
- Increased Program Cell Death-1 Expression on T Lymphocytes of Patients With Progressive Multifocal Leukoencephalopathy
- Creators
- Chen Sabrina Tan - Beth Israel Deaconess Medical CenterEvelyn Bord - Harvard UniversityThomas A. Broge - Harvard UniversityBrett Glotzbecker - Harvard UniversityHeidi Mills - Harvard UniversitySarah Gheuens - Harvard UniversityJacalyn Rosenblatt - Harvard UniversityDavid Avigan - Harvard UniversityIgor J. Koralnik - Harvard University
- Resource Type
- Journal article
- Publication Details
- Journal of acquired immune deficiency syndromes (1999), Vol.60(3), pp.244-248
- DOI
- 10.1097/QAI.0b013e31825a313c
- PMID
- 22549384
- PMCID
- PMC3400136
- NLM abbreviation
- J Acquir Immune Defic Syndr
- ISSN
- 1525-4135
- eISSN
- 1944-7884
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 5
- Grant note
- Pfizer Inc.; Pfizer T32AI007061 / NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID) Harvard Catalyst R01NS047029 / NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS) R01 NS 047029; NS 041198; K24 NS 060950; K08 NS 064215-01; T32 AI07387-21 / NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA Harvard University Merck Co.; Merck & Company UL1RR025758 / NATIONAL CENTER FOR RESEARCH RESOURCES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Research Resources (NCRR) UL1 RR 025758 / Harvard Clinical and Translational Science Center (NIH); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA P01CA155258 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Language
- English
- Date published
- 07/01/2012
- Academic Unit
- Iowa Neuroscience Institute; Internal Medicine
- Record Identifier
- 9984366283802771
Metrics
10 Record Views